2 Trials Testing Oral Varoglutamstat Now Enrolling in US, Europe

2 Trials Testing Oral Varoglutamstat Now Enrolling in US, Europe

310831

2 Trials Testing Oral Varoglutamstat Now Enrolling in US, Europe

Vivoryon Therapeutics is looking to enroll patients at different stages of Alzheimer’s disease for two ongoing, Phase 2 trials evaluating the safety and efficacy of its investigational oral treatment varoglutamstat. The therapy candidate has shown evidence, in earlier trials, of improving cognition, memory, and attention in Alzheimer’s patients, with “encouraging results after only 12 weeks of treatment,” the company said in a press release. The first trial, a Phase 2b study called VIVIAD (NCT04498650), is currently…

You must be logged in to read/download the full post.